ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 31-03-2023

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance that the investment objectives of the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care - TRI 1.32 -4.79 -9.30 22.40 11.45 12.76

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 -6.74 23.57 15.14 2.00 4,267.60
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 -1.95 24.09 13.04 2.20 1,574.52
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 -8.66 21.42 11.73 2.54 655.16
Tata India Pharma & Healthcare Fund-Regular Plan-Growth Dec 28, 2015 -7.60 21.13 13.72 2.44 485.91

Fund Holdings as on 28-February-2023

  • Sun Pharmaceutical Industries Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Cipla Ltd.

  • Apollo Hospitals Enterprise Ltd.

  • Alkem Laboratories Ltd.

  • Lupin Ltd.

  • Aurobindo Pharma Ltd.

  • Sanofi India Ltd.

  • Divi's Laboratories Ltd.

  • FDC Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Natco Pharma Ltd.

  • Gland Pharma Ltd.

  • Aster DM Healthcare Ltd.

  • Fortis Healthcare Ltd.

  • IPCA Laboratories Ltd.

  • Glaxosmithkline Pharmaceuticals Ltd.

  • SBI Life Insurance Company Ltd.

  • Indoco Remedies Ltd.

  • Biocon Ltd.

  • Viatris Inc.

  • ICICI Lombard General Insurance Company Ltd.

  • TREPS

  • Krsnaa Diagnostics Ltd.

  • Rainbow Childrens Medicare Ltd

  • Narayana Hrudayalaya Ltd.

  • Syngene International Ltd.

  • 91 Days Treasury Bills

  • Ajanta Pharma Ltd.

  • Zydus Lifesciences Ltd.

  • Windlas Biotech Ltd.

  • Dishman Carbogen Amcis Ltd.

  • Laurus Labs Ltd.

  • Alembic Pharmaceuticals Ltd.

  • Cash Margin - Derivatives

  • Dr. Reddy's Laboratories Ltd. (Covered call) $$

  • SBI Life Insurance Company Ltd. (Covered call) $$

  • Cipla Ltd. (Covered call) $$

  • Divi's Laboratories Ltd. (Covered call) $$

  • Sun Pharmaceutical Industries Ltd. (Covered call) $$

  • Apollo Hospitals Enterprise Ltd. (Covered call) $$

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Insurance

  • Miscellaneous

View More

About ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Scheme Analysis

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ICICI Prudential Mutual Fund. It was launched on 13-Jul-2018 and currently has an AUM of ₹2,538.10 crore. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care - TRI as secondary index.

The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund ended up ₹0.11(0.59%)yesterday to ₹18.64.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is managed by Dharmesh Kakkad .

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100